Dynavax Technologies Corporation (NASDAQ: DVAX) stock jumped a whopping 81.6% in after-hours trading Friday because of a favorable 12-to-1 advisory committee vote for its experimental hepatitis-B vaccine, Heplisav-B. This panel of independent experts was charged with assessing the vaccine’s safety profile for the U.S. Food and Drug Administration, which they deemed sufficient to warrant approval.